A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 4, 2015, Pages 791-803

  Panoilia, Eirini ^a   Schindler, Emilie ^b   Samantas, Epaminontas ^c   Aravantinos, Gerasimos ^c   Kalofonos, Haralabos P ^d   Christodoulou, Christos ^e   Patrinos, George P ^a   Friberg, Lena E ^b   Sivolapenko, Gregory ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e METROPOLITAN HOSPITAL   (Greece)

Author keywords

Bevacizumab; Colorectal cancer; Population modeling; VEGF; VEGF polymorphisms

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN 165; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN BINDING; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BINDING AFFINITY; BLOOD LEVEL; BODY WEIGHT; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL STUDY; COMPARTMENT MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; DEMOGRAPHY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG PROTEIN BINDING; ELIMINATION RATE CONSTANT; FEMALE; GENOTYPE; HUMAN; LIMIT OF DETECTION; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RECOMMENDED DRUG DOSE; REGRESSION ANALYSIS; SOLID TUMOR; BIOLOGICAL MODEL; BLOOD; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925463593     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2701-3     Document Type: Article

References (52)

1. Avastin-H/C/000582-II/65 (2014) European Public Assessment Report. The European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp curl=pages/medicines/human/medicines/000582/human-med-000663.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 20 Aug 2014
2. Final Labeling Text, BLA 125085 (2013) Center for Drug Evaluation and Research. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125085s285lbl.pdf. Accessed 20 Aug 2014
3. Avastin® (2014) Genentech USA, Inc. http://www.avastin.com/patient cid=gne-WE-00000083. Accessed 20 Aug 2014
4. Parikh SS, Mehta HH, Desai BI (2012) Advances in development of bevacizumab, a humanized antiangiogenic therapeutic monoclonal antibody targeting VEGF in cancer cells. Int J Pharm Biomed Sci 3:155-163
5. Tabrizi M, Roskos LK (2006) Exposure-response relationships for therapeutic biologic products. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs. Principles and case studies in drug development. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 295-327
6. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
7. Pavlidis ET, Pavlidis TE (2013) Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol 19:5051-5060
8. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777-794
9. Kemik O, Kemik AS, Sümer A, Purisa S, Dulger AC, Begenik H, Hasirci ̄, Tuzun S (2011) Preoperative vascular endothelial growth factor levels as a prognostic marker for stage II or III colorectal cancer patients. Cancer Growth Metastasis 4:25-32
10. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270-278
11. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K (1998) Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 93:249-252
12. Kazazi-Hyseni F, Beijnen JH, Schellens JHM (2010) Bevacizumab. Oncologist 15:819-825
13. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14:62-66
14. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816
15. DeMichele A, Fox KR (2009) Optimizing outcomes with bevacizumab by better targeting patients and tumors. Oncology 23:339-340
16. Glassman PM, Balthasar JP (2014) Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med 11:20-33
17. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83-124
18. Bender BC, Schindler E, Friberg LE (2013) Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol. doi: 10.1111/bcp.12258
19. Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharmacol. doi: 10.1038/psp.2012.4
20. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev 10:84-96
21. Ma P (2012) Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res 29:866-882
22. Gibiansky L, Gibiansky E (2010) Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37:323-346
23. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 5:803-812
24. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591
25. Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB, Stewart CF (2014) Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 20:2783-2792
26. Lu J, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786
27. Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P, Pesenti E, De Nicolao G (2013) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemother Pharmacol 71:1147-1157
28. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H (2011) Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum 54:1026-1035
29. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G (2011) Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 104:1262-1269
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guide-line (version 1.1). Eur J Cancer 45:228-247
31. Ternant D, Cézé N, Lecomte T, Degenne D, Duveau AC, Watier H, Dorval E, Paintaud G (2010) An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit 32:647-652
32. Quantikine® human VEGF immunoassay (2014) R&D Systems Inc., Minneapolis, USA. http://www.rndsystems.com/pdf/dve00.pdf. Accessed 10 Sept 2014
33. Shendure JA, Porreca GJ, Church GM, Gardner AF, Hendrickson CL, Kieleczawa J, Slatko BE (2011) Overview of DNA sequencing strategies. Curr Protoc Mol Biol 96:7.1.1-7.1.23
34. DNA sequencing by capillary electrophoresis (2009) Applied Biosystems chemistry guide. https://www3.appliedbiosystems.com/cms/groups/mcb-support/documents/generaldocuments/cms-041003.pdf. Accessed 11 Sept 2014
35. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64
36. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257
37. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11:558-569
38. Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329-332
39. Wählby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252
40. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151
41. Keizer RJ, Karlsson MO, Hooker A (2013) Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. doi: 10.1038/psp.2013.24
42. McLeay SC, Morrish GA, Kirkpatrick CM, Green B (2012) The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51:319-330
43. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171-185. doi: 10.1007/s10456-011-9249-6
44. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293:865-881
45. Gaudreault J, Greig G, Cosson V, Gupta M, Jumbe N, Hooker AC (2008) Population pharmacokinetics of bevacizumab. J Clin Oncol 26:abstr 14570
46. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
47. Min BS, Kim NK, Jeong HC, Chung HC (2012) High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Oncol Lett 4:123-130
48. Hansson EK, Amantea MA, Westwood P, Milligan PA, Houk BE, French J, Karlsson MO, Friberg LE (2013) PKPD modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. CPT Pharmacomet Syst Pharmacol. doi: 10.1038/psp.2013.61
49. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS (2010) Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 70:9886-9894
50. Hsei V, Deguzman GG, Nixon A, Gaudreault J (2002) Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 19:1753-1756
51. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104:18363-18370
52. Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE (2007) Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 13:5341-5347